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Abstract
We have estimated the pharmacological sensitivity and synergism of 125 individual patient samples for all
drugs and combination treatments for acute myeloid leukemia in the context of the overall patient population.
Each ex vivo pharmacological proﬁle identiﬁes drugs and treatments for which the patient’s malignant cells are
particularly sensitive or resistant, assisting in the selection of individualized treatments.
Background: We have evaluated the ex vivo pharmacology of single drugs and drug combinations in malignant cells
of bone marrow samples from 125 patients with acute myeloid leukemia using a novel automated ﬂow cytometrye
based platform (ExviTech). We have improved previous ex vivo drug testing with 4 innovations: identifying individual*This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).
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306 -leukemic cells, using intact whole blood during the incubation, using an automated platform that escalates reliably
data, and performing analyses pharmacodynamic population models. Patients and Methods: Samples were sent
from 24 hospitals to a central laboratory and incubated for 48 hours in whole blood, after which drug activity was
measured in terms of depletion of leukemic cells. Results: The sensitivity of single drugs is assessed for standard
efﬁcacy (EMAX) and potency (EC50) variables, ranked as percentiles within the population. The sensitivity of drug-
combination treatments is assessed for the synergism achieved in each patient sample. We found a large vari-
ability among patient samples in the dose-response curves to a single drug or combination treatment. Conclusion:
We hypothesize that the use of the individual patient ex vivo pharmacological proﬁles may help to guide a personalized
treatment selection.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 14, No. 4, 305-18ª 2014 The Authors. Published by Elsevier Inc. All rights reserved.
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Acute myeloid leukemia (AML) is the most common acute leu-
kemia affecting adults.1 AML is an extremely heterogeneous disease,
with > 50 cytogenetic and molecular genetic markers identiﬁed to
date.1-10 These genetic markers, along with patient-related factors,
are used to deﬁne several subtypes of AML, with treatment and
prognosis varying among subtypes.11 Genomic and molecular ﬁnd-
ings have helped stratify patients to guide treatment selection,3,4,12-15
and new strategies are necessary to individualize treatments.
Current efforts to personalize treatments in hematological neo-
plasms, such as AML, rely mostly on genomic and genetic prog-
nostic factors, which stratify rather than individualize patients for
treatments.16 A more direct approach would be to evaluate the
pharmacological activity of drugs directly in the individual patient’s
bone marrow sample (ex vivo). Ex vivo assays for detecting cell
death inducible by drugs for hematological neoplasms have been in
development for over 35 years. There now exist several functional
assays for detecting activity in ex vivo samples, collectively known as
individualized tumor response testing (ITRT).17 The term refers
speciﬁcally to studies that measure the effect of different treatments
against cancer on live tumor cells from an individual patient,
excluding measurements in subcellular fractions, animal samples, or
cell lines.17,18 However, current ITRT methods have signiﬁcant
limitations that have restricted their clinical usefulness.
We have developed a method to test a patient’s bone marrow
sample ex vivo, using a novel automated ﬂow cytometryebased
screening system called ExviTech (ex vivo Technology), which may
overcome previous barriers for these assays. The purpose of this
study was to examine the ex vivo pharmacology of single drugs used
to treat AML, and combinations of these drugs, against the ma-
lignant cell population in bone marrow samples from 86 to 125
AML patients, characterizing the speciﬁc-patient pharmacodynamic
parameters to guide treatment individualization.
Patients and Methods
Patients
Vivia-PMAML (Study of the correlation between the ex vivo
response to antineoplasic drugs and their efﬁcacy in the treatment of
AML), a noninterventional and prospective study, included bone
marrow (BM) samples from adult patients over 18 years of age whoClinical Lymphoma, Myeloma & Leukemia August 2014were diagnosed with de novo AML in Spanish centers from the
Programa Español de Tratamientos en Hematología (PETHEMA)
group. All patients gave informed consent for study participation.
Bone marrow samples from 177 patients from 26 hospitals
participating in the study were enrolled from September 2011 to
August 2012 at the moment of this interim analysis. Of these, 52
samples were not evaluable by the laboratory. Finally, 125 bone
marrow samples from adult AML patients were successfully incu-
bated for 48 hours and analyzed to characterize the cytotoxic effect
of drugs used for the treatment of AML. We have received clinical
response information for 78 of the 125 samples reported. These 78
samples were from patients with an average age of 57 years (range,
26-88 y); 45 patients were male and 33 female.
Methods
Figure 1 displays the overall method of data acquisition: On day
1, the patient sample was received. A small part was separated for
validation, and the majority was diluted with culture media and
plated into 96-well plates previously prepared with the desired drugs
and drug combinations. The number of live leukemic cells seeded in
each well was ﬁxed between 8000 and 32,000, depending on the
percentage of leukemic cells for each sample. These plates were
incubated for 48 hours and analyzed on day 3. Antibodies shown
were added to identify leukemic cells using a gating strategy based
on forward scatter (FSC) or side scatter (SSC) and expression or lack
of expression of different surface markers. The monoclonal anti-
bodies selection was performed to optimize the identiﬁcation of
leukemic cell in each sample. The aim of our analysis is not the
phenotypic characterization but only the identiﬁcation of these cells.
According to this, the markers that Euroﬂow19 has pointed out as
the “backbone markers” for AML, CD34, CD45, CD117, and
human leukocyte antigeneDR (HLA-DR), were included in our
combination. They allowed us to identify the leukemic cells in
almost 90% of AML patients. This allowed for the selection of the
2 best antibodies for unequivocal identiﬁcation of the pathological
cell population in each particular sample. We used 3 antibody
combinations: CD117/CD45 for 56% of samples, CD34/CD45
for 31%, and HLADR/CD45 for 13%. Live leukemic cells were
identiﬁed by their light scatter properties classiﬁed as high, inter-
mediate, or low (FSCint/hi/SSCint) in the absence of annexin-
Figure 1 Data-Acquisition Workﬂow. The Illustration Shows the Data-Acquisition Workﬂow From the Reception of Sample day 1
(top Left), to Validation (Bottom Left) and Plating With Drugs (Bottom Left). Plates Were Incubated for 48 Hours and Analyzed
on day 3 (Right Panel). Antibodies Shown Were Added to Identify Leukemic Cells (top Right Panel), and Within Those,
Annexin-VeFITC Staining (Bottom Right) was Used to Identify Apoptotic vs. Live Cells (Bottom Right)
Abbreviations: BM ¼ bone marrow.
Teresa A. Bennett et alVeﬂuorescein isothiocyanate (FITC) staining. FSC/SSC selection
was performed to exclude debris. The average percentage of cell
viability on receipt of the sample was 80%, and samples were only
processed if the viability was greater than 50%.
Sample Validation. BM samples were extracted under sterile
conditions and were received in the laboratory within 24 hours of
extraction. Initial analysis evaluated the number of pathological
cells and their viability. All reagents and drugs were obtained from
Sigma (St. Louis, MO) unless otherwise noted. Brieﬂy, different
volumes of sample (1 mL, 3 mL, 5 mL, and 7 mL) were aliquoted in
duplicate into a 96-well plate. To lyse red blood cells, 180 mL
of ammonium chloride lysis solution was added to each well (2 g
KHCO3, 16.58 g NH4Cl, 0.074 g Na2-ethylenediaminetetraacetic
acid [EDTA]2H2O, H2O to 1 L). Following a 10-minute incu-
bation period at 4C, each plate was centrifuged for 5 minutes at
1200 rpm and the supernatant removed. The lysis step was per-
formed twice. To analyze, 20 mL of a combination of annexin-
VeFITC (Immunostep, Salamanca, Spain), binding buffer (BB)
(2.4 g 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid [HEPES],
8.19 g NaCl, 0.37 g Cl2Ca, H2O to 1 L), and the following
monoclonal antibodies (MoAbs) were added to each well: CD117
(clone 104D2)-PE (Becton Dickinson, San Jose, CA), CD34 (clone
581)-PerCP (BioLegend, San Diego, CA), HLADR (clone L243)-PB
(BioLegend), and CD45 (HI30)-PO (Life Technologies, Carlsbad,
CA).20 After 15 minutes of incubation at room temperature in the
dark, a wash step was performed using BB solution. The pellet was
resuspended in 30 mL BB for analysis in Vivia’s ExviTech platform.
Cell count and viability on arrival were computed and the optimal
volume of sample to use per well was determined.Assay Preparation. The whole sample was diluted with Roswell
Park Memorial Institute (RPMI) 1640, supplemented with 20%
(vol/vol) FBS (Thermo Scientiﬁc, Waltham, MA), 2% HEPES, 1%
antibiotic (Zell Shield, Labclinics, Barcelona, Spain), and 1%
L-glutamine 200 mM (Lonza, Hopkinton, MA) to a ﬁnal volume of
60 mL per well. The mixture was dispensed into 96-well plates
containing the drugs with a Multidrop Combi Smart (Thermo
Scientiﬁc, Waltham, MA). Drug plates were previously prepared
using an Echo 550 Liquid Handler (LabCyte, Sunnyvale, CA). For
each drug, 8 concentrations, adjusted to cover the range of activities
across patients, were used. The drugs tested were idarubicin (IDA),
daunorubicin (DAU), mitoxantrone (MIT), etoposide (ETO),
cytarabine (CYT), ﬂudarabine (FLU), clofarabine (CLO), and
6-thioguanine (THIO). Each drug was analyzed in 86 to 125
patient samples. The plates were incubated for 48 hours at 37C in
humidiﬁed air containing 5% CO2.
Isolating the Leukocyte Population. To prepare the sample for
analysis, at the end of the incubation, the red cell population was
lysed following the same procedure as described in the previous
section. Then 20 mL of a combination of the 2 best MoAbs for
identifying the leukemic cell population for the sample (as deter-
mined previously) and annexin-VeFITC were added to each well,
and the plates were incubated for 15 minutes at room temperature
in the dark. A wash step was performed using BB, and the pellet was
resuspended in 20 mL of BB for analysis in Vivia’s ExviTech
platform.
ExviTech Platform. This novel ﬂow cytometry based system in-
corporates a CyAn ADP cytometer (Beckman Coulter, Brea, CA)Clinical Lymphoma, Myeloma & Leukemia August 2014 - 307
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308 -and Vivia’s novel End Point Sampler (EPS) plate handler (Saryna
Technologies, San Diego, CA). The EPS aspirated the contents of
each well of the assay plate, and it delivered the contents to the ﬂow
cell of the cytometer. Each 96-well assay plate was collected as a
single .fcs ﬁle from the CyAn cytometer. The EPS was run from the
same computer as the cytometer, recording a second ﬁle for each
plate. This timing ﬁle was integrated with the .fcs ﬁle for data
analysis by our proprietary software program, FCS Analyzer (Saryna
Technologies). This program was designed to separate the acquired
data from the cytometer into speciﬁc groups and assign well
numbers to each group. Each 96-well plate was then analyzed as a
single ﬁle, and each well could be examined individually as needed.
Data Analysis. Summit software (Beckman Coulter) was used for
the initial analysis. Identiﬁcation of pathological cells was performed
using a gating strategy based on FSC/SSC and expression or lack of
expression of the different MoAb markers. We did not measure
apoptosis; we measured depletion. Depletion was measured as the
difference in the number of live cells in a well with drugs vs. the
control wells without drugs. Hence, once the pathological cell
subset was identiﬁed, we use annexin-V to exclude dying cells and
measure only the number of live cells, in the drug wells and in the
control wells. Those cells without annexin-V staining and appro-
priate FSC/SSC were considered live cells.21 As the results of our
analysis relied on the number of live cells remaining at the end of
the assay, it was sufﬁcient to identify this population using FSC/
SSC and lack of staining with annexin-VeFITC. There was no
need to distinguish between apoptosis and necrosis, and necrotic
leukocytes change in both FSC and SSC, and thus the use of
propidium iodide was not deemed necessary. Using the above pa-
rameters, FCS Analyzer was used to determine the effect of each of
the individual drugs. Data was transferred to ActivityBase (IDBS,
Guildford, UK), our data base program for ﬁnal analysis.
Population Pharmacodynamic Modeling. In this evaluation, drug
response was measured using the absolute number of live malignant
cells. For each monotherapy treatment, the response vs. concen-
tration relationship was described following the population
approach with NONMEM 7.2.22 The estimation method used for
the current pharmacokinetic evaluation was the First Order Con-
ditional Estimation (FOCE) with the INTERACTION option.
Data were logarithmically transformed for the analysis. Interpatient
variability was modeled exponentially, avoiding negative parameters
for certain patients. Residual error was described using an additive
error model on the logarithmic scale. Because response measure-
ments were observed after a single incubation time (ie, 48 h),
steady-state conditions were assumed during analysis. The sigmoidal
EMAX model (see equation 1) was ﬁt to the response (E) vs. con-
centration (C) data:
E ¼ E0 
"






E represents response in terms of the absolute number of live
malignant cells; E0 represents the absolute number of malignant
cells alive after incubation for 48 hours without any drugs. WeClinical Lymphoma, Myeloma & Leukemia August 2014estimate the response of any drug at a given concentration by the
number of malignant cells left alive after 48 hours of incubation.
The efﬁcacy is quantiﬁed by the parameter EMAX and is the
maximum decrease fraction in response with respect to baseline that
the drug is able to induce. The potency is quantiﬁed by the
parameter EC50 and is the value of drug concentration eliciting half
of EMAX, and g is the parameter controlling the steepness of the
response vs. concentration curve. During analysis, both the typical
and participant-speciﬁc estimates of IMAX were constrained between
0 and 1 using the logistic transformation. For presentation of data,
the survival index was computed, with the number of live leukemic
cells in control wells that were not exposed to any drugs being set as
100%. The number of live cells in each drug-treated well was
compared with this control value, and the survival index for each
drug at each concentration was determined as the percentage of live
pathologic cells at every tested concentration.
Interpatient variability (IPV) was associated with each of the
previously deﬁned pharmacodynamic parameters. Interpatient
differences were also allowed for the variance accounting for the
residual variability. In this analysis, the covariate effects of the
patient characteristics were not explored. The pharmacodynamic
interactions among 2 or 3 drugs in combination treatments was
characterized by computing the standard combination index (CI) as
deﬁned by Chou & Talalay,23 which is a parameter representing
synergism.
Results
Whole Sample vs. Isolated Leukocytes
We have pioneered using a whole sample rather than isolated
leukocytes to incubate patient primary cells with the drugs.24
Leukocytes were isolated only after incubation, when drug-
induced cell death had already occurred in the whole-sample
environment. Figure 2 shows the signiﬁcant differences in the
pharmacological behavior for both methods. The top panel shows
the dose responses of IDA and CYT on 1 patient sample in terms of
their survival index, the percentage of live cells relative to control
wells without drug, which decreases as drug concentration increases
toward the right. Dose responses using whole sample are colored
blue, and those using isolated leukocytes are colored red. Whereas
IDA shows a signiﬁcant shift in its potency or EC50 of nearly
10-fold, CYT shows no difference. The lower panels show the same
comparison for each drug in terms of their EC50 (potency) values
for 8 patient samples. The middle panel shows differences in
potency for CYT ordered from largest to smallest; the ﬁrst 3 samples
show large differences, whereas the last 6 samples show no signiﬁ-
cant differences. The bottom panel shows the potency differences
for the same 9 samples for IDA: Differences in potency for IDA are
not related to differences for CYT, as the top-panel example shows.
In most cases, isolated leukocytes have higher potency and lower
EC50s, compared with those of the whole sample.
Pharmacological Proﬁles Ex Vivo of Single Drugs
The pharmacological properties potency, estimated as the EC50
(effective concentration inducing 50% cell death), and efﬁcacy,
estimated as the EMAX (effective maximum response), were deter-
mined for each drug in each sample. The pharmacodynamic
parameters for the 8 tested drugs are shown in Table 1, and their
Figure 2 Whole Sample vs. Isolated Leukocytes. (A) Dose-Response Curves for Idarubicin (IDA) and Cytarabine (CYT) in Isolated
Leukocytes and Whole Sample. Data, From Sample 6 Below, Display a Logarithmic Difference in the Potencies (EC50s) for IDA
but Equal Results for CYT. (B) The EC50 (y-Axis) of the Whole Sample and the Isolated Leukocyte Fraction From 9 Patient
Samples With CYT. (C) The EC50 of the Same Samples With Idarubicin
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310 -average dose-response curves, obtained by simulating the typical
parameter estimates (Table 1), are shown in Figure 3A. (Note that
population models refer to typical rather than average values, with an
equivalent meaning.) The survival index is displayed on the y-axis,
starting at 100% and decreasing with increasing drug concentration.
All drugs tested show a signiﬁcant measurable effect at depleting
leukemic AML blast cells ex vivo, in a dose-dependent manner, with
signiﬁcant differences among drugs. Curves to the left show the
death of AML blasts at lower concentrations and are thus more
potent than right-shifted curves. There was good correspondence
between median potency of the drugs and their generally perceived
clinical efﬁcacy. Starting from the left, active at lower doses, we see
the cluster of the 3 potent anthracyclines IDA, MIT, and DAU
(blue). These are followed by the group of nucleoside analogues
(red), starting from the left, with CLO, FLU, CYT, and THIO.
CLO stands out because its average dose-response curve shows
submaximal efﬁcacy (EMAX); it cannot kill all AML blasts. CYT and
FLU have a similar behavior, better than CLO but on average unable
to induce complete leukemic cell death. THIO was the least potent
drug tested, and its EMAX was ﬁxed to 0 to improve the ﬁtting (IPV
not estimated in Table 1). This is shown in Table 1 by the 0 or nearTable 1 Pharmacological Population Parameters. Individual Drug T
Values for Efﬁcacy (EMAX) and Potency (EC50) are Shown o
Expressed as Coefﬁcient of Variation (%); Synergism (Righ
Median and Standard Error
Single-Drug Pharmacology
DRUG n
Efﬁcacy (EMAX) % Survival Potency (
Typical RE Typical
IDA 125 0a e 0.106
DAU 109 0a 0 0.592
MIT 110 0.5 0.2 0.233
ETO 110 0.1 0.1 18.5
CYT 125 11.8 4 2.28
FLU 125 15.0 3.2 1.43
CLO 122 29.0 5.1 0.92















Abbreviations: CLO ¼ clofarabine; CYT ¼ cytarabine; DAU ¼ daunorubicin; ETO ¼ etoposide; FLU ¼
aEstimate is not signiﬁcantly different from 0.
Clinical Lymphoma, Myeloma & Leukemia August 20140 values of their typical EMAX values and the minimal IPV of their
EMAX. For IDA and DAU, the EMAX was ﬁxed to (complete
response) rather than calculated, improving the accuracy of the
population-model ﬁtting, and their IPV was hence not estimated.
In order to more fully evaluate the range of patient-speciﬁc
responses, we have estimated the IPV in drug responses. The
range of the IPV can be seen in Figure 3B. The individual dose-
response curves for FLU (gray) are displayed in the background of
the average dose responses shown in Figure 3A. The individual dose
responses of FLU cover a wide range, some reaching left into the
area of the potent anthracyclines, and for other patients, to the right
into the range of the weakest drugs. Thus, ex vivo interpatient
variability is a factor to be taken into consideration and is as
important as the commonly used relative strength of the average
dose-response curves of these drugs.
Figure 4 shows the complete set of each individual patient dose
response (gray) for the 8 drugs tested. The red line is the average
response, as displayed in Figure 3. Among the anthracyclines,
sensitivity represented by their potencies is more variable for
MIT (IPV ¼ 221) than IDA (IPV ¼ 157) or DAU (IPV ¼ 135),
as can be observed in their dose-response curves in Figure 4. ETOypical and Random (Variability and Residual Error [RE])
n the Left Side. Estimates of Interpatient Variability (IPV) are
t Side) is Computed Using the Combination Index (CI), Showing
EC50) mM IPV-EMAX IPV-EC50
RE Typical RE Typical RE
0.016 ne 157 0.15
0.13 ne 135 0.17
0.22 1.2 0.69 221 0.14
0.13 0.3 0.41 141 0.17
0.13 32 0.21 105 0.25
0.19 25 0.24 113 0.41
0.019 36 0.2 142 0.25















ﬂudarabine; IDA ¼ idarubicin; MIT ¼ mitoxantrone; ne ¼ not estimated; THIO ¼ 6-thioguanine.
Figure 3 Interpatient Variability for a Single Drug Covers the Average Activity of All Drugs. (A) Median Curves From 8 Drugs. The
Survival Index (y-Axis) Ranges From 100% to 0%, Displaying the Selective Acute Myeloid Leukemia Cell Depletion Calculated
With Population Models. (B) The Curves From Part A Overlaid on 125 Individual Dose-Response Curves to Fludarabine (Gray)
Abbreviations: CLO ¼ clofarabine; CYT ¼ cytarabine; DAU ¼ daunorubicin; ETO ¼ etoposide; FLU ¼ ﬂudarabine; IDA ¼ idarubicin; MIT ¼ mitoxantrone; THIO ¼ 6-thioguanine.
Teresa A. Bennett et albehaves like the anthracyclines, albeit with a signiﬁcantly lower
potency (higher EC50). Maximal efﬁcacy or EMAX, ie, when all
blast are eliminated at the highest doses, occurs for essentially
all samples for the 3 anthracyclines, IDA, DAU, and MIT, and
ETO. Among nucleosides, the magnitude of their potency IPV for
CYT, FLU, and CLO are roughly similar, with CLO showing a
slightly higher value, varying more among patient samples.
However, when considering the variability in their efﬁcacies or
EMAX, only the nucleosides display variability for this parameter.
The efﬁcacy IPVs of CYT, FLU, and CLO are signiﬁcant
(25-36%) and similar. This variability, in combination with the
submaximal efﬁcacy of these drugs, shows that for a signiﬁcant
number of patient samples, these drugs are not capable of
inducing 100% cell death in the leukemic population. THI is the
weakest nucleoside, and for most of the samples, it is neitherpotent nor effective. As 100 mM was the highest drug concen-
tration we could achieve for physical solubility limit, for most
samples a full dose-response curve was not obtained. For analysis
of this data, we have set the EMAX value to 0 to enable the
population models to calculate an EC50 value. Because of this, the
IPV of the EMAX was not estimated. However, a very small subset
of samples were shown to be highly sensitive (left shift), in which
all blasts were eliminated (EMAX ¼ 0), indicating that for these
very few patients, the drug or combination could potentially be an
effective treatment option.
Pharmacological Proﬁles Ex Vivo of Drug-Combination
Treatments
Synergism for the 12 main drug-combination protocols used
across Europe was evaluated by calculating the CI from ChouClinical Lymphoma, Myeloma & Leukemia August 2014 - 311
Figure 4 Average and Individual Dose Responses ex vivo for AML Drugs. Dose-Response Analysis was Completed for 8 Individual
Drugs in Bone Marrow Samples From 86 to 125 Patients With Acute Myeloid Leukemia. The Survival Index (y-Axis) Ranges
From 100% to 0%, Displaying the Selective Acute Myeloid Leukemia Cell Depletion Calculated With Population Models. The
Gray Lines Display Each Individual Response, With the Median Response Shown in red. Panels are Shown for (A) Idarubicin,
(B) Mitoxantrone, (C) Daunorubicin, (D) Etoposide, (E) Cytarabine, (F) Clofarabine, (G) Fludarabine, and (H) 6-Thioguanine
Pharmacological Proﬁles of Acute Myeloid Leukemia
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Figure 5 Population Proﬁles of the Synergism of 12 Drug-Combination Treatments. The Population Proﬁles of the Synergism of
the 12 Drug-Combination Treatments Were Estimated by the Combination Index (CI). Values of CI of 1 Were Considered
Additive, < 1 Were Considered Synergism (Right Shift), and > 1 Were Considered Antagonistic (Left Shift). The Distribution of
Values Across the Population is Shown by a box Plot; the Median CI is at the Center as a Vertical bar, With its Standard Error
Shown as a Dotted Line. The box Covers the 25th to 75th Percentiles of the Population, and the Horizontal Bars Extend to
10th (Left) and 90th (Right) Percentiles of the Population
Abbreviations: CLO ¼ clofarabine; CYT ¼ cytarabine; DAU ¼ daunorubicin; ETO ¼ etoposide; FLU ¼ ﬂudarabine; IDA ¼ idarubicin; MIT ¼ mitoxantrone; THIO ¼ 6-thioguanine.
Teresa A. Bennett et aland Talalay.23 In this analysis, a value of 1 is an additive
response, a value < 1 indicates a synergistic response, and a value
> 1 reﬂects an antagonistic response. The CIs at 4 different levels
of response (20%, 40%, 60%, 80%) were calculated and theaverage reported in Table 1. The CI is graphically displayed in
Figure 5, in terms of percentiles across the population, using a
box plot. This representation enables us to compare the syner-
gism for all 12 drug-combination treatments. All treatments areClinical Lymphoma, Myeloma & Leukemia August 2014 - 313
Figure 6 Interpretation of Population Dose Responses
Converting Them to Population Percentile Ranking.
The Figure Illustrates Cytarabine Dose Responses
for 125 Samples (Gray), Showing a Sensitive Sample
(Left Green), an Average Sample (red), and a
Resistant Sample (Right Green). The Potencies
(EC50s) for These 125 Curves are Represented as
a Rank Order (in the Bottom box) in Terms of
Percentiles of the Population. The Sensitive Sample
(Green Left) is Represented as a Green bar Close to
the Best Potency (100%) and the Resistant Sample
as a Green bar Close to the Worst Potency (0%).
Average Sample is the 50% Percentile. Efﬁcacy
(EMAX) is Represented to the Right of 100%-0%
Potency box Only When There is a Signiﬁcant % of
Resistant Cells (for Example, 18% in red)
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314 -synergistic on average, as their medians are < 1. The differences
shown in Figure 5 among the median synergism (CI) for all
treatments are not substantial given their standard error (hori-
zontal dotted lines).
More remarkable are the different levels of IPV, shown by the
horizontal stretch for each treatment. Variability was highest
among the CYT-DAU, CYT-MIT-ETO, and CYT-CLO combi-
nations. Interestingly, for a subset of patient samples, these 3
combinations induced an antagonistic response (bar extending to
the left of 1). This ﬁnding was particularly so for the CYT-DAU
combination, which had a CI of 0.743 (Table 1), a score closer
to an additive interaction than any of those tested. In comparison,
CYT-MIT-ETO had a CI of 0.421, among the lowest CIs recor-
ded, thus one of the most synergistic. Thus, these synergistic in-
dexes provide 2 different inferences for any individual patient
sample; ﬁrst, the relative position of a given sample on this synergy
map identiﬁes its ranking among the population of patient samples,
whether an individual patient sample may be especially synergistic
or not compared with the population of patient samples. Second,
the absolute value indicates whether there is synergism or not for a
given treatment for that sample.
The responses to CYT-DAU and CYT-CLO were quite variable
among patient samples, compared with that of CYT-IDA and even
that of CYT-MIT. Their patterns are signiﬁcant in that CYT-DAU
stretches more toward additive-antagonism whereas CYT-IDA and
CYT-MIT have a longer arm toward synergism. This means there
are patients for whom clinicians would like to avoid the combina-
tion CYT-DAU, as it is antagonistic. Similarly, for the CYT-CLO
combination, a subset of samples displays a highly synergistic
value, whereas for another subset, the value is additive-antagonistic.
The combinations of 3 drugs also displayed large differences in
IPV. For instance, CYT-MIT-ETO shows a much higher IPV than
CYT-IDA-ETO or CYT-DAU-ETO, equivalent combinations
exchanging the anthracycline MIT, IDA, or DAU. However, the
same combinations with ETO removed show different IPV proﬁles,
with CYT-DAU showing a higher IPV than that of CYT-MIT
and that showing higher than that of CYT-IDA. Hence adding
ETO to CYT-IDA, CYT-DAU, or CYT-MIT changes substantially
the relative IPV of these cytarabine-anthracycline combinations.
The most clinically relevant information that can be extracted
from these series of dose-response curves on patient samples is the
relative ranking of each individual, for each drug or combination
treatment, within the entire population of patient samples. As an
example, CYT, as seen in Figure 6, has a subset of samples whose
curves are shifted left of the average, 1 of which is colored green. For
this patient sample, CYT is more potent than average, thus a low
dose may be sufﬁcient to kill the leukemic blast cells. This ﬁnding
means this patient’s ex vivo sample is especially sensitive to this
drug. Alternatively, those curves shifted rightward mean that this
drug needs high doses to kill blasts from these patients’ ex vivo
samples; this ﬁnding means the patient ex vivo sample highlighted
in green is especially resistant toward this drug (CYT). To capture
this population ranking, we use the percentiles diagram below the
dose-response curves of Figure 6; a single patient sample potency
(EC50), shown in green, is ranked with a given percentage, such that
the most sensitive patient for a drug, the one whose line is farthest to
the left, is the one for whom the drug is most potent and is thusClinical Lymphoma, Myeloma & Leukemia August 2014ranked 100%. Conversely, the most resistant patient sample,
farthest to the right, is the one for which the drug is least potent and
is thus ranked 1%. Note that potency ranks 1%-100% go in the
direction opposite to that of drug concentration (minimum to
maximum) because a potent drug (high percentage) would eliminate
patient cells with a low EC50 concentration. Furthermore, a subset
of a patient’s leukemic cells may be resistant to a speciﬁc drug, as
seen in the Figure 6 dose responses whose lines at the highest doses
do not reach zero. In the following scheme, the dose response to
represent the population pharmacological proﬁle, we report this as
the percent survival of malignant cells (in red, to the right of the
percentile-ranking scheme).
The individual pharmacological proﬁles for 2 patients are shown
in Figure 7. The relative drug potency for 2 patient samples, ie
their ranking within the population, is shown in the left panels of
Figure 7. For display purposed, the ranking order is reversed from
that shown in Figure 6. In the left column the relative potencies for
the 8 drugs for that patient sample are shown from 1-100%, most
potent to the right, opposite to the drug concentration direction
shown in Figure 6. The right columns in Figure 7 show the syn-
ergism of the drug combinations for that patient sample. The CI for
each combination is shown in green, relative to the population
proﬁle.
Figure 7 Pharmacological Population Proﬁles for 2 Acute Myeloid Leukemia Patient Samples. The Pharmacological Population
Proﬁles for (A) Patient Sample 1 and (B) Patient Sample 2, Showing the Population Ranking of the Samples Relative to
Individual Drugs (Left) and Synergism in Their Combination Treatments (Right). Individual Patient Values are Shown as
Green Bars With Horizontal Green Error Bars. High Sensitivity or Resistance to Drugs or Synergisms for Each Sample, Deﬁned
as Values Within the Population’s Best or Worst 20th Percentile, are Highlighted With Boxes of Green (Sensitive) or red
(Resistant). (A) The First Patient Sample was Very Sensitive (Green Boxes) to Cytarabine (CYT) and Fludarabine (FLU)
(Albeit With 15% Resistant Cells), and Lack of Synergy (red Boxes) for the CYTeIdarubicin (IDA) Combination and the
CYTeDaunorubicin (DAU) Combination. (B) The Second Patient Sample was Very Sensitive to FLU and Clofarabine (CLO)
(Green Boxes), With Lack of Synergism for the CYT-FLU, CYT-IDA-FLU, CYT-IDAeEtoposide (ETO), and CYT-CLO
Combinations (red Boxes)
Abbreviations: MIT ¼ mitoxantrone; THIO ¼ 6-thioguanine.
Teresa A. Bennett et alFigure 7A illustrates data of an individual resistant patient treated
with CYT-IDA, on these population pharmacological proﬁles. The
most remarkable extreme phenotypes are highlighted by colored
boxes. This patient sample is especially sensitive to CYT and FLU
with potencies > 90% (green boxes), and is not synergistic for the
CYT-IDA and CYT-DAU combination treatments (red boxes).
The best individual drugs, CYT and FLU, can be combined in atreatment with good synergism (linked by green arrows). However,
FLU has 15% potentially resistant cells. This patient was treated
with CYT-IDA (red arrows) and was resistant. The potency of IDA
is average, which means it is acceptable because it is an efﬁcacious
drug, and for CYT, the potency is excellent—within the top 10% of
most sensitive patients. However, there is a lack of synergism for the
CYT-IDA treatment in the right-hand panel. The lack of clinicalClinical Lymphoma, Myeloma & Leukemia August 2014 - 315
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316 -response would suggest the lack of synergism prevails over the good
sensitivity of the individual drugs, highlighting synergism as a
potential key predictor of clinical outcome. Interestingly, ETO
eliminates only half of the blasts for this patient, and CLO is
inadequate in both sensitivity and the presence of potentially
resistant clones. Its synergy proﬁle is interesting in that, although
it lacks synergism for CYT-IDA, it shows good synergism for
CYT-FLU and the 3-drug combination CYT-IDA-FLU.
Figure 7B shows a patient in whom the most extreme pharma-
cological proﬁles do not converge into the right treatment. The
most remarkable features for this patient are that the sample is
very sensitive to FLU and CLO (green boxes) and has strong lack
of synergism for several combination treatments (marked by a red
box): CYT-FLU, CYT-CLO, CYT-IDA-FLU, and CYT-IDA-
ETO. These proﬁles are inconsistent with a good treatment link-
ing individual drug potencies and synergistic treatments ex vivo,
because the most sensitive drugs, FLU and CLO, can be combined
best as CYT-FLU and CYT-CLO, but both treatments are non-
synergistic. (This is shown for CYT-FLU as red arrows). The poor
synergism of CYT-IDA-FLU may just be a reﬂection of the poor
synergism of CYT-FLU, in spite of good, albeit not extreme, syn-
ergism for CYT-IDA. Actually, CYT-IDA has good drug potencies
and synergism (shown by green arrows), even though none is an
extreme best cases. In fact, this patient was treated with CYT-IDA,
which achieved complete response. The potency of the individual
drug IDA is very good, signiﬁcantly right shifted, within the top
25% among the patient population. The potency for CYT is average
at 50%, which is a good percentile because, on average, CYT is an
efﬁcacious drug. The right-hand panel shows that the synergy for
CYT-IDA for this patient is quite good, within the top 25% among
patients. These 3 good ex vivo pharmacological variables are
consistent with the complete response achieved.
Discussion
We have developed a cell-based screening platform, called Exvi-
Tech, which incorporates both automated sample preparation and
automated evaluation by ﬂow cytometry, in conjunction with
proprietary analytical software and a database structure geared for
rapid data acquisition, analysis, and reporting of results. By testing
patient samples directly and in whole sample, we expect to bring
the effectiveness of a given drug in vitro a step closer to what it is
expected to do in vivo. The large level of variability among patient
responses illustrates what is already known, that AML patients do
not always respond well to treatments given according to standard
protocols. There are 4 factors that distinguish the drug-sensitivity
platform presented here. First is the use of the complete patient
BM sample, retaining the erythrocyte population and serum pro-
teins, and thus measuring pharmacological activity in a better
approximation of their biological context. Second, using multi-
parametric ﬂow cytometry to analyze the samples allows for the use
of labeled monoclonal antibodies and annexin-VeFITC; this en-
ables speciﬁc identiﬁcation of the malignant cell population and
determination of the number of live cells at the end of the assay.
Third, a proprietary platform with extensive automation greatly
expands the scope of analysis that can be done with each patient
sample, enabling 8-point dose responses for drugs andClinical Lymphoma, Myeloma & Leukemia August 2014combinations, and it increases the quality of the test by eliminating
human error at several points in the process. Fourth, data is analyzed
using population pharmacodynamic models, most often used to
model clinical trial results, that ﬁt pharmacological data for all pa-
tients simultaneously. This signiﬁcantly enhances the accuracy of
the individual patient pharmacological values, and diminishes
considerably the associated error by ﬁlling in missed or error-prone
data. All 4 points diminish the associated error and avoids artifacts
resulting in signiﬁcantly more reliable ex vivo pharmacological data
for individual patient samples. The developments integrate previous
efforts to promote ex vivo testing in AML,17,25-29 and they incor-
porate novelties that may enable the use of pharmacology data in
patient samples for individualized patient treatment.
The translation from ex vivo sensitivity or resistance to patient
responses is obviously not direct. Other data that may inﬂuence the
interpretation includes pharmacokinetic, adsorption, distribution,
metabolism, excretion, and other factors. These factors are expected
to be less important in extreme cases of dose-response curves shifted
maximally toward the left (sensitive) or toward the right (resistant),
and more dominant in intermediate cases. Thus, the clinically more
relevant data are the extremes, and for each patient we look among
all drugs and all combination treatments for extreme sensitivities or
extreme resistances, as shown for Figure 7. Additionally, this
approach cannot account for the role of the marrow microenvi-
ronment.30,31 The microenvironment has been shown to increase
chemoresistance,30 and thus it may affect ex vivo sensitivity but less
so ex vivo resistance.
There are potential clinical inferences from this set of rather
complete pharmacological data for AML drugs and treatments
measured on freshly extracted patient samples. However, we should
be very cautious of correlating ex vivo pharmacology with patient
responses directly. The rank order of absolute median potencies
ex vivo for each drug is consistent with clinical observations (Fig. 3).
When the dose response of a drug for an individual patient shows
that it is unable to eliminate all blasts at maximum doses, which can
be referred as low efﬁcacy or low EMAX, it means there is subset of
cells (possibly a clone) resistant or highly resistant to that drug. This
occurs particularly for CLO, FLU, and CYT, in this order. How-
ever, in this experiment incubation was for 48 hours, whereas in
clinical practice, drugs are given over multiple days in patterns of
administration not represented in this pharmacological assay. If it is
a truly resistant clone, then multiple days and doses would not
eliminate it, and this single drug pharmacology assay is clinically
relevant. We plan to evaluate whether synergism of combination
treatments can eliminate this resistant population, or if increasing
the incubation time to 72 or 96 hours is effective at eliminating
these populations. Nonetheless, if the pharmacological proﬁle shows
that other drugs are more sensitive for this patient sample, it would
seem wise to prevent administering treatments with a clear possi-
bility of leaving resistant cells. We thus represent incomplete blast
death as “potentially resistant clones” and as a warning sign pending
further investigation. For the related nucleosides CYT, FLU, and
CLO, there are a considerable percentage of samples (CYT 22%,
FLU 32%, CLO 51%) in which the drug fails to eliminate all blasts,
even at drug concentrations that are higher than that achieved
in vivo. However, this lack of full efﬁcacy stratiﬁes quite well these
Teresa A. Bennett et aldrugs, identifying 22%-51% of the population that may not be
quite suitable to them. Excluding these patients may improve the
response rate signiﬁcantly, in clinical practice and in clinical trials.
This approach may thus be suitable as a companion diagnostics in
clinical trials, and to proﬁle drug candidates in discovery and
development.
We have characterized the pharmacological responsiveness of in-
dividual patient samples to available AML drug treatments by
comparing the potency and efﬁcacy of individual drugs with the
synergism of the drug-combination treatment. Over time, clinical
correlation data will indicate which of these variables is more impor-
tant for clinical efﬁcacy of a given treatment in an individual patient.
Synergism represents a more integral component of the combination
treatment, whereas single-drug strength represents the starting point
for synergism. We hypothesize that the use of the individual patient
ex vivo pharmacological proﬁles such as those shown in Figure 7 may
help to guide a personalized treatment selection.26
Guidelines can be derived ﬁrst from the extreme phenotypes,
when an individual patient sample is highly sensitive or resistant to
speciﬁc drugs, or very synergistic or antagonistic to speciﬁc com-
bination treatments. However, in only a few cases do we identify
the perfect case, highly sensitive drugs that are also highly synergistic
in an approved combination treatment. More often, we need to
evaluate choices that include submaximal efﬁcacy and synergism,
and thus this approach may represent valuable information to the
hematologist who must interpret it based on her/his know how and
the increasing number of prognostic factors.1-9
Conclusion
In conclusion, we have developed an improved a methodology
to measure the pharmacological activity of drugs and drug combi-
nations in AML patient samples as well as to model their phar-
macological behavior. This information may be useful in selecting
the optimal treatment of the individual patient. By testing the drugs
used in the treatment protocols for AML directly on patient sam-
ples, a pharmacologically based model has been developed to infer
drug resistance or sensitivity, patient by patient. IDA, DAU, and
MIT are commonly used in combination with CYT, and testing
may be able to determine which would be better for each individual
patient. To derive guidelines in interpreting these results, clinical
correlation studies are ongoing with PETHEMA to validate these
inferences for observational studies, to be followed by future
interventional studies.Clinical Practice Points
 Evaluating the efﬁcacy of drug compounds in eliminating tumor
cells directly in patient samples has been performed for more
than 30 years. Yet this seemingly direct way to assess the sensi-
tivity of each drug towards individual patient samples never
achieved clinical validation. Hence, its use fell off as the genomic
revolution offered great promises.
 We have identiﬁed and overcome the key issues hindering ex
vivo pharmacological evaluation of drugs in patient samples,
especially with the use of whole bone marrow samples. The results are a large variability between patients of their dose
response curves, opening a new dimension versus the consider-
ation only of the average drug activity. The variability of Flu-
darabine covers the whole range of the average dose responses of
the standard drugs in AML.
 Synergism between combined drugs can now be measured reli-
ably. There is also a large interpatient variability in the synergism
between drugs that form a given treatment, such as Cytarabine-
Idarubicine.
 Different drugs and different treatments based on drug combi-
nations show different degrees of interpatient variability in their
single drug activity and their synergism. This means there is
potential in leveraging these data to personalize treatment to
individual patients.
 Clinical validation of this new data is still necessary before this new
approach can deliver valuable information to the hematologists.Acknowledgments
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